Breakout Setups
IONS appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
IONIS PHARMACEUTICALS INC (IONS) Stock Price & Overview
NASDAQ:IONS • US4622221004
Current stock price
74.055 USD
-0.81 (-1.09%)
Last:
The current stock price of IONS is 74.055 USD. Today IONS is down by -1.09%. In the past month the price increased by 5.47%. In the past year, price increased by 152.09%.
IONS Key Statistics
52-Week Range29.42 - 86.74
Current IONS stock price positioned within its 52-week range.
1-Month Range68.9 - 77.375
Current IONS stock price positioned within its 1-month range.
- Market Cap
- 12.233B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.44
- Dividend Yield
- N/A
IONS Stock Performance
Today
-1.09%
1 Week
-0.11%
1 Month
+5.47%
3 Months
-6.74%
Longer-term
6 Months +5.66%
1 Year +152.09%
2 Years +81.46%
3 Years +111.68%
5 Years +74.85%
10 Years +82.74%
IONS Stock Chart
IONS Stock Screens
IONS currently appears in the following ChartMill screener lists.
IONS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IONS. When comparing the yearly performance of all stocks, IONS is one of the better performing stocks in the market, outperforming 93.44% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
IONS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IONS. IONS has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
IONS Earnings
On February 25, 2026 IONS reported an EPS of -1.41 and a revenue of 203.00M. The company missed EPS expectations (-4.63% surprise) and beat revenue expectations (27.5% surprise).
Next Earnings DateApr 29, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported-$1.41
Revenue Reported203M
EPS Surprise -4.63%
Revenue Surprise 27.50%
IONS Forecast & Estimates
29 analysts have analysed IONS and the average price target is 97.94 USD. This implies a price increase of 32.25% is expected in the next year compared to the current price of 74.055.
For the next year, analysts expect an EPS growth of -71.66% and a revenue growth -7.84% for IONS
Analysts
Analysts81.38
Price Target97.94 (32.25%)
EPS Next Y-71.66%
Revenue Next Year-7.84%
IONS Groups
Sector & Classification
IONS Financial Highlights
Over the last trailing twelve months IONS reported a non-GAAP Earnings per Share(EPS) of -2.44. The EPS increased by 19.74% compared to the year before.
Income Statements
Revenue(TTM)943.71M
Net Income(TTM)-381.39M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.82% | ||
| ROE | -77.98% | ||
| Debt/Equity | 3.88 |
Chartmill High Growth Momentum
EPS Q2Q%-113.64%
Sales Q2Q%-10.57%
EPS 1Y (TTM)19.74%
Revenue 1Y (TTM)33.83%
IONS Ownership
Ownership
Inst Owners105.86%
Shares165.19M
Float163.83M
Ins Owners0.62%
Short Float %8.75%
Short Ratio6.55
IONS Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.79 | 360.314B | ||
| AMGN | AMGEN INC | 15.03 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.43 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.76 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.79 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.57 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.42 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IONS
Company Profile
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,402 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Company Info
IPO: 1991-05-17
IONIS PHARMACEUTICALS INC
2855 Gazelle Court
Carlsbad CALIFORNIA 92010 US
CEO: Brett P. MONIA
Employees: 1402
Phone: 17609319200
IONIS PHARMACEUTICALS INC / IONS FAQ
What does IONS do?
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 1,402 full-time employees. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
What is the stock price of IONIS PHARMACEUTICALS INC today?
The current stock price of IONS is 74.055 USD. The price decreased by -1.09% in the last trading session.
Does IONIS PHARMACEUTICALS INC pay dividends?
IONS does not pay a dividend.
How is the ChartMill rating for IONIS PHARMACEUTICALS INC?
IONS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of IONIS PHARMACEUTICALS INC (IONS) based on its PE ratio?
IONIS PHARMACEUTICALS INC (IONS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.44).
What is the market capitalization of IONS stock?
IONIS PHARMACEUTICALS INC (IONS) has a market capitalization of 12.23B USD. This makes IONS a Large Cap stock.